Baxalta Inc. / Sigma-Tau Finanziaria S.p.A. (Oncaspar portfolio)

Acute Lymphoblastic Leukemia (ALL)

7K US cases/yr · $100M Oncaspar global net sales ~2014 (cited in deal materials)

Disease Overview

Acute lymphoblastic leukemia is a rapidly progressing cancer of immature lymphoid white blood cells that overwhelm normal hematopoiesis. It is the most common pediatric cancer (>80% of childhood leukemias) but also occurs in adults with markedly worse prognosis. Asparaginase-containing multi-agent regimens are foundational to curative therapy.

Competitive Landscape

At deal time the asparaginase market was effectively a Sigma-Tau monopoly: native E. coli L-asparaginase (Elspar, discontinued in the US in 2012) had been replaced by Oncaspar (pegaspargase) as standard first-line therapy in pediatric and AYA ALL, with Erwinaze (asparaginase Erwinia chrysanthemi, Jazz Pharmaceuticals) reserved for hypersensitivity rescue. Calaspargase pegol — the next-generation, longer-half-life pegylated asparaginase in the acquired portfolio — was positioned to extend dosing intervals and replace Oncaspar over time. Outside asparaginase, the competitive set included Pfizer's Besponsa (inotuzumab ozogamicin, R/R B-ALL) and Amgen's Blincyto (blinatumomab, MRD/R-R B-ALL), both targeted agents used in relapsed/refractory settings rather than displacing front-line asparaginase. The acquisition gave Baxter BioScience (which spun out as Baxalta in July 2015) a marketed oncology asset with $100M in annual sales, peak potential of ~$500M, and a follow-on biologic (calaspargase pegol, FDA-approved December 2018 as Asparlas) to defend the franchise. Shire then acquired Baxalta in 2016, and the portfolio ultimately landed at Servier in 2020.